10/01/20 The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AGLE-102™ for the treatment of patients with DEB. Evangelos Badiavas, MD, PhD, Chief Scientific Officer at Aegle Therapeutics said, “This designation will expedite the development and regulatory review of AGLE-102 and highlights the importance…

9/29/20 Aegle Therapeutics Corporation, a first-in-class biotechnology company developing extracellular vesicles as therapy, today announced the completion of a $6.5M Series A round of financing.
Aegle is also pleased to announce the appointment of Heidi Kempinski as Senior Vice President, Head of Operations…